Search

Your search keyword '"Mornex, F."' showing total 1,152 results
Start Over Author "Mornex, F."
1,152 results on '"Mornex, F."'

151. Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by stereotactic body radiation therapy

Author

Pracht, M., primary, Chajon, E., additional, de Baere, T., additional, Nguyen, F., additional, Bronowicki, J.-P., additional, Vendrely, V., additional, Baumann, A.-S., additional, Croisé-Laurent, V., additional, Rio, E., additional, Rolland, Y., additional, Le Sourd, S., additional, Gustin, P., additional, Perret, C., additional, Mornex, F., additional, Peiffert, D., additional, Merle, P., additional, and Deutsch, E., additional

Published
2018
Full Text
View/download PDF

153. A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis

Author

Chajon, E., primary, Pracht, M., additional, De Baere, T., additional, Nguyen, F., additional, Bronowicki, J., additional, Vendrely, V., additional, Baumann, A., additional, Croisé-Laurent, V., additional, Rio, E., additional, Rolland, Y., additional, Le Sourd, S., additional, Gustin, P., additional, Perret, C., additional, Mornex, F., additional, Peiffert, D., additional, Merle, P., additional, and Deutsch, E., additional

Published
2018
Full Text
View/download PDF

160. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

Author

Clavien, Pa, Lesurtel, M, Bossuyt, Pm, Gores, Gj, Langer, B, Perrier, A, OLT for HCC Consensus Group Abecassis, M, Balabaud, C, Barritt, Gj, Belghiti, J, Bhoori, S, Bossuyt, P, Breitenstein, S, Broelsch, C, Bruix, J, Burra, Patrizia, Burroughs, A, Busuttil, R, Charlton, M, Cherqui, D, Colombo, Ml, D'Albuquerque, C, D'Alessandro, A, de Santibañez EJ, Dufour, F, Durand, F, Dutkowski, P, Duvoux, C, El Serag, H, Fan, St, Finn, Rs, Fisher, R, Forner, A, Freeman, R, Fung, J, Geier, A, Germani, G, Gores, G, Gouw, As, Grant, D, Greig, P, Gurusamy, K, Hanto, D, Heaton, N, Heim, M, Hemming, A, Hippen, B, Hisham, A, Hubscher, S, Ichida, T, Kahn, D, Kew, M, Kita, Y, Kiuchi, T, Klintmalm, Gb, Kneteman, N, Kojiro, M, Kudo, M, Lee, Jm, Lee, Sg, Lencioni, R, Lerut, J, Livraghi, T, Llovet, J, Lo, Cm, Lodge, P, Maccaughan, G, Madoff, D, Majno, P, Marcellin, P, Marrero, J, Mazzaferro, V, Mergental, H, Merle, P, Miksad, R, Mornex, F, Müllhaupt, B, Olthoff, K, Paradis, V, Pestalozzi, B, Pomfret, E, Poon, R, Porte, R, Prasad, Kr, Raptis, D, Roskams, T, Rossi, M, Samuel, D, Schlitt, H, Schwartz, M, Sexton Dobby AM, Shaked, A, Sherman, M, Siegler, M, Suh, Ks, Todo, S, Toso, C, Trevisani, F, Trotter, Jj, Valdecasas, Gj, Vauthey, N, Vilgrain, V, Villamil, F, Vonlanthen, R, Wald, C, Weber, A, Wiesner, R, Wright, L, Yao, F, Zheng, Ss, Zucman Rossi, J., P.A.Clavien, M. Lesurtel, P.M. Bossuyt, G.J. Gore, B. Langer, A. Perrier, on behalf of the OLT for HCC Consensus Group […, F. Trevisani, and …]

Subjects
medicine.medical_specialty, Carcinoma, Hepatocellular, Waiting Lists, medicine.medical_treatment, media_common.quotation_subject, MEDLINE, 030230 surgery, Liver transplantation, Milan criteria, Risk Assessment, Article, RECOMMENDATIONS, 03 medical and health sciences, 0302 clinical medicine, Jury, Risk Factors, Liver Neoplasms/mortality/surgery, medicine, hepatocellular carcinoma, liver transplantation, Humans, HEPATOCELLULAR CARCINOMA, Hepatocellular/mortality/surgery, Tissue Donors/supply & distribution, media_common, ddc:616, Evidence-Based Medicine, business.industry, Patient Selection, Liver Neoplasms, Carcinoma, LIVER TRANSPLANTATION, Evidence-based medicine, medicine.disease, Tissue Donors, Neoadjuvant Therapy, 3. Good health, Surgery, Treatment Outcome, Oncology, Family medicine, Donation, Hepatocellular carcinoma, Liver Transplantation/adverse effects/mortality/standards, 030211 gastroenterology & hepatology, Working group, business
Abstract

Although liver transplantation is a widely accepted treatment for hepatocellular carcinoma (HCC), much controversy remains and there is no generally accepted set of guidelines. An international consensus conference was held on Dec 2–4, 2010, in Zurich, Switzerland, with the aim of reviewing current practice regarding liver transplantation in patients with HCC and to develop internationally accepted statements and guidelines. The format of the conference was based on the Danish model. 19 working groups of experts prepared evidence-based reviews according to the Oxford classification, and drafted recommendations answering 19 specific questions. An independent jury of nine members was appointed to review these submissions and make final recommendations, after debates with the experts and audience at the conference. This report presents the final 37 statements and recommendations, covering assessment of candidates for liver transplantation, criteria for listing in cirrhotic and non-cirrhotic patients, role of tumour downstaging, management of patients on the waiting list, role of living donation, and post-transplant management.

Published
2012
Full Text
View/download PDF

162. Dose de tolérance à l’irradiation des tissus sains : le poumon

Author

Mornex F and Ortholan C

Subjects
medicine.medical_specialty, Lung, business.industry, Cumulative dose, Radiography, External beam radiation, Normal tissue, Pulmonary function testing, medicine.anatomical_structure, Oncology, Dose-Limiting, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Radiology, business, Complication
Abstract

Radiation pneumonitis is the most common dose limiting complication of thoracic radiation. Clinically significant radiation pneumonitis usually develops in 10-20% of patients. Characteristic clinical features associated with radiation pneumonitis include dyspnea, non-productive cough, radiographic opacification confined to the outlines of the field of radiation treatment and changes in pulmonary function measures. The risk of radiation pneumonitis is related to the cumulative dose of radiation to normal tissue and to patients and tumor features. Some studies demonstrated that preexisting pulmonary lung dysfunction, tumour location in lower lobes, use of concurrent chemotherapy could increase the risk of radiation pneumonitis. Controversies persist about which dosimetric parameter optimally predicts the risk of radiation pneumonitis. Mean lung dose, V20 and V30 are the most studied parameters. However, no ideal dosimetric parameter has been identified. The objective of this review is to summarize predictive factors of radiation pneumonitis, and to evaluate the predictive ability of various dose-volume histogram parameters for routine practice.

Published
2010

163. Carcinome hépatocellulaire unifocal Child A : l’association de radiothérapie et de chémoembolisation transartérielle est-elle équivalente à la résection chirurgicale ?

Author

Darfaoui, M., primary, Mornex, F., additional, Rode, A., additional, Radenne, S., additional, Manichon, A.-F., additional, Fares, N., additional, Prévost, C., additional, Ouziel, G., additional, Hartig-Lavie, K., additional, Pages-Écochard, M., additional, Ducerf, C., additional, Lesurtel, M., additional, Mabrut, J.-Y., additional, and Merle, P., additional

Published
2017
Full Text
View/download PDF

165. [Adaptive radiation therapy for non-small cell lung cancer]

Author

Bibault, J.-E., Arsène-Henry, A., Durdux, C., Mornex, F., Hamza, S., Trouette, R., Thureau, S., Faivre, J.-C., Boisselier, P., Lerouge, D., Paragios, N., Giraud, P., Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), and Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)

Subjects
Radiotherapy, Intensity modulation, Conformal, Radiotherapy Planning, Computer-Assisted, Radiothérapie adaptative, Uncertainty, Image-guided, Carcinome bronchique, [SDV.CAN]Life Sciences [q-bio]/Cancer, Lung neoplasms, Carcinoma, Non-Small-Cell Lung, Humans, Incertitude anatomique, Modulation d’intensité, Radiothérapie conformationnelle
Abstract

International audience; Anatomical changes and tumor regression during thoracic radiotherapy may alter the treatment volumes. These modifications are not taken into account into set-up or motion margins used for treatment planning. Their dosimetric impact could be significant and a better understanding of the changes occurring during the 6 to 7 weeks of treatment could be useful in order to define quantitative thresholds before a new treatment planning is needed. Margins could also be reduced in order to better spare organs at risk and perform targeted dose escalation. This review assesses the potential of morphologic and metabolic imaging during treatment for adaptive radiotherapy in non-small cell lung cancer.

Published
2015

166. 1470P - First real life data on durvalumab after definitive concomitant chemoradiotherapy (cCRT) in unresectable stage (St) III non-small cell lung cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) temporary authorization of use (ATU)

Author

Avrillon, V., Bota Ouchlif, S., Merle, P., Pichon, E., Stancu, A.T., Chouaid, C., Sire, C., Boudabous, H., Lagrange, A., Sabatini, M., Eberst, G., Boisselier, P., Gourion, A., Lion, A., Lahouegue, A., Belkhiria, K., de La Porte, I., Urbieta, M., Mornex, F., and Girard, N.

Published
2019
Full Text
View/download PDF

168. [Editorial]

Author

Taillandier, L., Le Rhun, É., Métellus, P., Mornex, F., Mazeron, J.-J., Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), SALZET, Michel, and Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
Brain Neoplasms, [SDV]Life Sciences [q-bio], Congresses as Topic, Medical Oncology, 030218 nuclear medicine & medical imaging, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Oncology, Neurology, 030220 oncology & carcinogenesis, Humans, Radiology, Nuclear Medicine and imaging, France, ComputingMilieux_MISCELLANEOUS, Societies, Medical
Abstract

International audience

Published
2014

169. [Stereotactic body radiation therapy and oligometastases]

Author

Bourgier, Céline, Azria, David, Fenoglietto, Pascal, Riou, Olivier, Almaghrabi, M. Y., Supiot, S., Mornex, F., Giraud, P., Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), CRLCC Val d'Aurelle - Paul Lamarque, CRLCC René Gauducheau, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), and Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
Radiosurgery, Neoplasms/pathology/*surgery, Neoplasms, Patient Selection, didactique, Humans, Radiotherapy Dosage, [SDV.CAN]Life Sciences [q-bio]/Cancer, Neoplasm Metastasis, Neoplasm Metastasis/*therapy
Abstract

In stage IV cancers, locoregional management of primitive tumours as surgery and/or radiotherapy improved both progression-free survival and overall survival. Among metastatic cancer patients, some of them are considered as oligometastatic stage as they present few metastatic sites associated with low tumor aggressiveness. For those patients, metastatic local control, and therefore prolonged time to progression should be reached through local treatments as surgery and/or radiofrequency ablation and/or stereotactic radiotherapy. Here we propose a review of oligometastatic stage and results from extracranial stereotactic radiotherapy in terms of efficacy and tolerance.

Published
2014

170. FDG-PET during radio-chemotherapy is predictive of outcome at 1 year in non small cell lung cancer patients: a prospective multicentric study (RTEP2)

Author

Vera, P., Mezzani-Saillard, S., Edet-Sanson, A., Ménard, J.-F., Modzelewski, R., Thureau, S., Meyer, M.-E., Jalali, K., Lerouge, D., Houzard, C., Mornex, F., Olivier, P., Faure, Gérôme, Rousseau, C., Mahé, M.-A., Gomez, P., Brenot-Rossi, I., Salem, N., Dubray, B., Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Département de radiothérapie et de physique médicale, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de médecine nucléaire, Centre régional de lutte contre le cancer, Département de Radiothérapie, Centre René Gauducheau-Centre de Lutte Contre le Cancer Nantes Atlantique 'René Gauducheau' (CLCC)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), and UNICANCER-UNICANCER

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2014

174. Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Author

Guigay, J., primary, Chamorey, E., additional, Céruse, P., additional, Mornex, F., additional, Degardin, M., additional, Alfonsi, M., additional, Digue, L., additional, Berrier, A., additional, Artignan, X., additional, Cals, L., additional, Faivre, S., additional, Vuillemin, E., additional, Rolland, F., additional, Timochenko, A., additional, Babin, E., additional, Seronde-Delmas, A., additional, Prevost, A., additional, Romano, O., additional, Peyrade, F., additional, and Le Tourneau, C., additional

Published
2016
Full Text
View/download PDF

183. Abstract P3-12-18: Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of late toxicity after radiotherapy: Results of the prospective multicenter French trial

Author

Hennequin, C, primary, Azria, D, additional, Riou, O, additional, Castan, F, additional, Coelho, M, additional, Nguyen, TD, additional, Peignaux, K, additional, Lemanski, C, additional, Lagrange, J-L, additional, Kirova, Y, additional, Lartigau, E, additional, Belkacemi, Y, additional, Bourgier, C, additional, Noel, G, additional, Clippe, S, additional, Mornex, F, additional, Kramar, A, additional, Pèlegrin, A, additional, and Ozsahin, M, additional

Published
2016
Full Text
View/download PDF

184. PROCLAIM : résultats finaux de survie globale de l’essai de phase III : pemetrexed cisplatine ou étoposide cisplatine, plus radiothérapie thoracique suivie d’une chimiothérapie de consolidation dans le CBNPC non épidermoïde localement avancé

Author

Mornex, F., primary, Senan, S., additional, Hennequin, C., additional, Lartigau, E., additional, Brade, A., additional, Wang, L., additional, Vansteenkiste, J., additional, Dakhil, S., additional, Biesma, B., additional, Martinez Aguillo, M., additional, Aerts, J., additional, Govindan, R., additional, Rubio-Viqueira, B., additional, Lewanski, C., additional, Gandara, D., additional, Choy, H., additional, Mok, T., additional, Hossain, A., additional, Iscoe, N., additional, Treat, J., additional, Koustenis, A., additional, Chouaki, N., additional, and Vokes, E., additional

Published
2016
Full Text
View/download PDF

185. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01

Author

Fournel, Pierre, primary, Vergnenégre, Alain, additional, Robinet, Gilles, additional, Léna, Hervé, additional, Gervais, Radj, additional, Le Caer, Hervé, additional, Souquet, Pierre-Jean, additional, Chavaillon, Jean-Michel, additional, Bozonnat, Marie-Cécile, additional, Daurès, Jean-Pierre, additional, Chouaid, Christos, additional, Martel-Lafay, Isabelle, additional, Fournel, P., additional, Talabard, J.N., additional, Vergnenégre, A., additional, Melloni, B., additional, Decroisette, C., additional, Clavére, P., additional, Robinet, G., additional, Bayle, S., additional, Labat, J.P., additional, Léna, H., additional, Belleguic, C., additional, Benchalal, M., additional, Gervais, R., additional, Rivière, A., additional, Lerouge, D., additional, Souquet, P.J., additional, Gérinière, L., additional, D'Hombres, A., additional, Mornex, F., additional, Le Caer, H., additional, Tessier, E., additional, Ramos, H., additional, Chavaillon, J.M., additional, Chouaid, C., additional, Touboul, E., additional, Bota, S., additional, Thiberville, L., additional, Gallocher, O., additional, Quoix, E., additional, Mennecier, B., additional, Jung, G.M., additional, Falchero, L., additional, Paillotin, D., additional, Schouabe, S., additional, Jonveaux, E., additional, Bout, J.C., additional, Martin, P., additional, Perol, M., additional, Arpin, D., additional, Martel-Lafay, I., additional, Letreut, J., additional, Poirier, R., additional, Benyoub, A., additional, Vernejoux, J.M., additional, Trouette, R., additional, Dansin, E., additional, Berard, H., additional, Pietra, J.C., additional, Zalcman, G., additional, Thomas, P., additional, Zribi, A., additional, Milleron, B., additional, Lavolé, A., additional, Coetmeur, D., additional, Lamezec, B., additional, Bonnamour, C., additional, Grangeon, V., additional, Suchaud, J.P., additional, Créquit, J., additional, Ramdane, S., additional, Barre, P., additional, Zawadi, M.A., additional, Gimenez, C., additional, Barlesi, F., additional, Pignon, T., additional, Grivaux, M., additional, Blanchon, F., additional, Mandet, J., additional, Perdu, D., additional, Cauchois, A., additional, Delhoume, J.Y., additional, Kin, B., additional, Merle, P., additional, Janicot, H., additional, Verrelle, P., additional, Auliac, J.B., additional, Coscas, Y., additional, Ducolone, A., additional, Herman, D., additional, and Roquette, A., additional

Published
2016
Full Text
View/download PDF

189. Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial

Author

Barhoumi , M., Mornex , F., Bonnetain , Franck, Rougier , P., Mariette , C., Bouché , O., Bosset , J.-F., Aparicio , T., Mineur , L., Azzedine , A., Hammel , P., Butel , J., Stremsdoerfer , N., Maingon , P., Bedenne , L., Chauffert , B., Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Epidémiologie et d'Ecologie parasitaire, Institut Pasteur de Tunis, Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Grand Accélérateur National d'Ions Lourds (GANIL), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Pasteur de Tunis-Réseau International des Instituts Pasteur ( RIIP ), Grand Accélérateur National d'Ions Lourds ( GANIL ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), and Maquart, François-Xavier

Subjects
Male, MESH : Hematologic Diseases, MESH: Remission Induction, MESH: Combined Modality Therapy, Gastrointestinal Diseases, MESH : Antineoplastic Combined Chemotherapy Protocols, MESH : Aged, Kaplan-Meier Estimate, MESH : Gastrointestinal Diseases, Deoxycytidine, MESH : Radiotherapy, Conformal, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Proportional Hazards Models, MESH: Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, MESH : Female, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, MESH: Aged, MESH : Carcinoma, Pancreatic Ductal, MESH: Antimetabolites, Antineoplastic, MESH: Middle Aged, MESH : Antimetabolites, Antineoplastic, Remission Induction, Middle Aged, MESH : Adult, MESH: Hematologic Diseases, Combined Modality Therapy, MESH: Antineoplastic Combined Chemotherapy Protocols, MESH: Radiotherapy, Conformal, Disease Progression, MESH : Fluorouracil, Female, MESH: Disease Progression, Fluorouracil, MESH: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Adult, Antimetabolites, Antineoplastic, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Cisplatin, MESH : Kaplan-Meier Estimate, MESH : Deoxycytidine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Gastrointestinal Diseases, MESH: Kaplan-Meier Estimate, Aged, Proportional Hazards Models, MESH : Remission Induction, MESH: Humans, MESH: Carcinoma, Pancreatic Ductal, MESH : Humans, MESH: Deoxycytidine, MESH: Adult, MESH : Disease Progression, MESH : Proportional Hazards Models, Hematologic Diseases, Gemcitabine, MESH: Male, Pancreatic Neoplasms, MESH: Cisplatin, Cisplatin, Radiotherapy, Conformal, MESH : Combined Modality Therapy, MESH: Female, MESH: Fluorouracil, MESH : Pancreatic Neoplasms
Abstract

International audience; PURPOSE: To compare chemoradiation with systemic chemotherapy to chemotherapy alone in locally advanced pancreatic cancer. PATIENTS AND METHODS: One hundred and nineteen patients with locally advanced pancreatic cancer, with World Health Organization performance status of zero to two were randomly assigned to either the induction chemoradiation group (60 Gy, 2 Gy/fraction; concomitant 5-fluoro-uracil infusion, 300 mg/m(2) per day, days 1-5 for 6 weeks; cisplatin, 20 mg/m(2) per day, days 1-5 during weeks 1 and 5) or the induction gemcitabine group (GEM: 1000 mg/m(2) weekly for 7 weeks). Maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks) was given in both arms until disease progression or toxicity. RESULTS: Overall survival was shorter in the chemoradiation than in the gemcitabine arm (median survival 8.6 [99% confidence interval 7.1-11.4] and 13 months [8,9,9-18], p=0.03). One-year survival was, respectively, 32 and 53%. These results were confirmed in a per-protocol analysis for patients who received 75% or more of the planned dose of radiotherapy. More overall grades 3-4 toxic effects were recorded in the chemoradiation arm, both during induction (36 versus 22%) and maintenance (32 versus 18%). CONCLUSION: This intensive induction schedule of chemoradiation was more toxic and less effective than gemcitabine alone.

Published
2011

190. [A complete issue devoted entirely to hepatocellular carcinoma?]

Author

Mornex, F., Mazeron, J.-J., Merle, P., Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipe 16, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Humans, Carcinoma, Hepatocellular, MESH: Liver Neoplasms, Liver Neoplasms, Humans, [SDV.CAN]Life Sciences [q-bio]/Cancer, Periodicals as Topic, MESH: Carcinoma, Hepatocellular, ComputingMilieux_MISCELLANEOUS, MESH: Periodicals as Topic
Abstract

International audience

Published
2011

191. [Medical therapies for hepatocellular carcinoma]

Author

Merle, P., Mornex, F., Equipe 16, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), hospices civils de lyon, Hôpital de l'Hôtel Dieu [CHU-HCL], and Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)

Subjects
Carcinoma, Hepatocellular, MESH: Humans, MESH: Immunologic Factors, Liver Neoplasms, Interferon-alpha, Angiogenesis Inhibitors, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antimitotic Agents, digestive system diseases, MESH: Liver Neoplasms, MESH: Antimitotic Agents, Humans, Immunologic Factors, MESH: Antineoplastic Agents, MESH: Interferon-alpha, MESH: Carcinoma, Hepatocellular, MESH: Angiogenesis Inhibitors
Abstract

International audience; Medical therapies for hepatocellular carcinoma are limited. Standard antimitotic chemotherapies and hormonotherapies are inefficient. Only sorafenib, an antiangiogenic agent inhibiting the VEGF and PDGF receptors as well as MAP kinase pathway, has shown a significant benefit on patient survival. However, its indication is restricted to patients with multifocal hepatocellular carcinoma not responding to transarterial hepatic chemoembolization or patients with hepatocellular carcinoma invading the venous portal tract or spreading to lymph nodes or as distant visceral metastasis.

Published
2011

192. [Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma]

Author

Merle, P., Mornex, F., Equipe 16, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), hospices civils de Lyon, Hôpital de l'Hôtel Dieu [CHU-HCL], and Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)

Subjects
MESH: Combined Modality Therapy, Carcinoma, Hepatocellular, MESH: Humans, MESH: Liver Neoplasms, Liver Neoplasms, MESH: Radiotherapy, Conformal, Humans, [SDV.CAN]Life Sciences [q-bio]/Cancer, Chemoembolization, Therapeutic, Radiotherapy, Conformal, MESH: Carcinoma, Hepatocellular, Combined Modality Therapy, MESH: Chemoembolization, Therapeutic
Abstract

International audience; Hepatocellular carcinoma is a poor prognosis tumour. The potential curative therapeutic options are orthotopic liver transplantation, surgical resection and radiofrequency ablation. Unfortunately, only a minority of patients (around 20%) are eligible for these techniques. Thus, patients can benefit from palliative options, such as transarterial chemoembolization (TACE) or sorafenib that bring only modest benefit on survival. Conformal radiotherapy allows delivering high dose radiation within a precise tumour volume while sparing the surrounding liver parenchyma. As employed in monotherapy, conformal radiotherapy is highly efficient for small size hepatocellular carcinoma (

Published
2011

193. Radiation Induced CD8 T-Lymphocyte Apoptosis as a Predictor of Late Toxicity After Radiation Therapy: Results of the Prospective Multicenter French Trial

Author

Azria, D., primary, Riou, O., additional, Castan, F., additional, Coelho, M., additional, Nguyen, T.D., additional, Peignaux, K., additional, Lemanski, C., additional, Lagrange, J.L., additional, Kirova, Y.M., additional, Lartigau, E., additional, Belkacemi, Y., additional, Bourgier, C., additional, Noel, G., additional, Clippe, S., additional, Mornex, F., additional, Hennequin, C., additional, Kramar, A., additional, Pèlegrin, A., additional, and Ozsahin, E.M., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results